Free fatty acid receptors (FFARs) are G protein-coupled receptors (GPCRs) activated by free fatty acids (FFAs). The four well-characterized FFARs are FFAR1/GPR40, FFAR2/GPR43, FFAR3/GPR41, and FFAR4/GPR120. FFARs are categorized according to the chain length of FFA ligands that activate each FFAR; FFA2 and FFA3 are activated by short chain FFAs, mainly acetate, butyrate, and propionate. GPR84 is activated by medium-chain FFAs, whereas FFA1 and GPR120 are activated by medium- or long-chain FFAs. Thus, each FFAR can act as an FFA sensor with selectivity for a particular FFA carbon chain length derived from food or food derived metabolites. FFARs have been reported to have physiological functions such as facilitation of insulin and incretin hormone secretion, adipocyte differentiation, anti-inflammatory effects, neuronal responses, and taste preferences. These physiological functions of FFARs could be considered to regulate energy and immune homeostasis. Therefore, FFARs have been targeted in therapeutic strategies for the treatment of metabolic disorders including type 2 diabetes and metabolic syndrome.
Fasiglifam (Standard) 是 Fasiglifam (MS-X09941) 的分析标准品,用于研究及分析应用,而 Fasiglifam (TAK-875) 是一种有效的、可口服的、具有选择性的 GPR40 激动剂,EC50 值为 72 nM。
Fasiglifam (TAK-875) hemihydrate 是一种有效的、具有口服活性的选择性 GPR40 激动剂(EC50 值为 72 nM),可增强葡萄糖依赖性胰岛素分泌、改善 2 型糖尿病大鼠的高血糖,并可引起肝损伤。
GPR40 Activator 2是一种源自专利WO 2012147516 A1、WO 2012046869A1和WO 2011078371 A1的GPR40激动剂。
GPR40 Activator 3(compound SC)是一种有效的 GPR40 激活剂,通过 GPR40/PKD1/CD36 轴抑制 M2 巨噬细胞极化,从而减轻肺纤维化。
HDAC6-IN-61 (Compund 4e) 是一种 HDAC6 抑制剂 (IC50: 73 nM),其选择性优于其他 HDAC 异构体,同时也是 GPR40 的激活剂,可提高乙酰化微管蛋白 (tubulin) 和 ERK 磷酸化水平,可用于研究神经炎症,例如阿尔茨海默病。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号